Also known as EIDD-2801 or MK-4482.
2021. October 22. Countries included in the Merck/molnupiravir license.
2021. October 20. International landscape of molnupiravir patents.
2021. October 4. U.S. Government’s $1.2 Billion Contract for Merck’s Investigational COVID-19 Drug Molnupiravir Redacts IP Terms, Contains Donation Clause and Very Limited Technology Transfer License.
News Reports and Blogs from Others
2021. October 5. Sharon Lerner. Merck Sells Federally Financed COVID Pill to U.S. for 40 Times What it Costs to Make. The Intercept.
2020. September 8. Paul Levy. Why is Ridgeback Biotherapeutics Trying to Suppress Adverse Opinions by Issuing Frivolous Defamation Threats?
2020. June 25. Christopher Rowland. Hedge fund manager stands to profit on ‘flip’ of taxpayer-funded coronavirus drug: Emory University’s coronavirus pill EIDD-2801 highlights financial speculation on drugs developed with public investment. Washington Post.
Selected Company Releases
2021. October 11. Merck Press Release. Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults.
2021. October 1. Merck Press Release. Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study.
2021. April 27. Merck Press Release. Amid Humanitarian Crisis in India, Merck Announces Voluntary Licensing Agreements with Five Indian Generics Manufacturers to Accelerate and Expand Global Access to Molnupiravir, an Investigational Oral Therapeutic for the Treatment of COVID-19.
2021. April 15. Merck Press Release. Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-to-Moderate COVID-19.